Content
Special Groups
Human Immunodeficiency Virus (HIV)
Table 21.5 Immunisation for HIV Patients

References
- Benson, C. A., Andersen, J. W., Macatangay, B. J. C., Mailliard, R. B., Rinaldo, C. R., Read, S., Bozzolo, D. R., Purdue, L., Jennings, C., Keefer, M. C., Glesby, M., Tebas, P., Russell, A. F., Martin, J., Annunziato, P., Popmihajlov, Z., & Lennox, J. L. (2018). Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 67(11), 1712–1719. https://doi.org/10.1093/cid/ciy242247
- Pacanowski, J., Lacombe, K., Campa, P., Dabrowska, M., Poveda, J.-D., Meynard, J.-L., Poirot, J.-L., Fonquernie, L., & Girard, P.-M. (2012). Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999), 59(4), 360–367. https://doi.org/10.1097/QAI.0b013e318249de59